Brokers and banks usually stop taking bids earlier. Check the exact time with yours.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Capital Expenditure for Setting Up New Greenfield Unit at YEIDA
Financing construction, cleanroom setup, automated assembly lines, and testing equipment for the Medical Device Park facility.
Funding Working Capital Requirements
Supporting inventory stocking of reagents and components and financing trade receivables.
General Corporate Purposes
Meeting business growth expenses, regulatory compliance costs, and general corporate overheads.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
Avience Biomedicals Limited is an Indian medical technology and healthcare diagnostics company incorporated in December 2019 and headquartered in New Delhi. The company is engaged in the development, manufacturing, processing, and marketing of In-Vitro Diagnostic (IVD) medical products, diagnostic test kits, and related healthcare instruments. Its product portfolio spans rapid diagnostic kits for infectious diseases such as malaria, dengue, HIV, and hepatitis, alongside advanced molecular diagnostic kits, biochemistry analyzers, and hematology systems. The company operates a manufacturing unit in Noida, Uttar Pradesh, and distributes its healthcare diagnostic products to hospitals, diagnostic laboratories, government healthcare programs, and private healthcare institutions across India and select international export markets. Avience Biomedicals Limited conducts its operations through direct sales channels as well as an established nationwide distribution network of medical equipment stockists and regional dealers. With its public listing on the NSE Emerge SME platform, Avience Biomedicals Limited is expanding its production infrastructure by setting up a greenfield manufacturing facility at the Medical Device Park in YEIDA, Gautam Buddha Nagar, Uttar Pradesh. The new facility is designed to enhance automated manufacturing capacity, broaden product offerings in molecular diagnostics, and support growing domestic and international demand for specialized diagnostic solutions.
Avience Biomedicals Limited raised Rs 8.52 crore from 4 anchor investors at a price of Rs 208 per share, allocating 4,09,800 equity shares.
Source: RHP • Analysis provided for informational purposes
Last Updated: 21 August 2026, 6:16 PM
Comprehensive Portfolio of In-Vitro Diagnostic Products
The company manufactures a wide array of rapid test kits, molecular diagnostics, and laboratory analyzers catering to diverse clinical testing requirements.
In-House Manufacturing and Quality Certifications
Operating specialized production facilities in Noida with regulatory approvals enables quality control and cost-competitive manufacturing.
Expanding Domestic and International Footprint
An established distribution network across Indian states along with growing export channels supports steady market expansion.
Regulatory and Quality Standard Compliance
Medical device manufacturing is subject to stringent health regulatory oversight and periodic quality audits; non-compliance could affect operations.
Raw Material Dependency and Supplier Concentration
Production relies on specialized chemical reagents, enzymes, and electronic components, making margins sensitive to input cost swings.
Capital Intensity of Production Expansion
The construction of the new manufacturing unit at YEIDA requires significant ongoing capital outlay and execution management.
Avience Biomedicals Limited
Unit No-2, 1st Floor, C-11, C Block, Community Centre, Janakpuri, New Delhi - 110058, India
View on Maps →Skyline Financial Services Private Limited
No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.